作者: Saiedeh Razi Soofiyani , Tohid Kazemi , Farzaneh Lotfipour , Akbar Mohammad hosseini , Dariush Shanehbandi
DOI: 10.3109/21691401.2015.1129618
关键词: Cancer research 、 Immunohistochemistry 、 Cancer 、 Transfection 、 Lipofectamine 、 Immunotherapy 、 Genetic enhancement 、 Pathology 、 Interleukin 12 、 Fibrosarcoma 、 Medicine
摘要: Context Immunotherapy is among the most promising modalities for treatment of cancer. Recently, interleukin 12 (IL-12) has been used as an immunotherapeutic agent in cancer gene therapy. IL-12 can activate dendritic cells (DCs) and boost anti-tumor immune responses. Objective In current study, we have investigated if therapy lead to regression tumor mass a mouse model fibrosarcoma. Material methods To investigate therapeutic efficacy IL-12, WEHI-164 were transfected with murine-IL12 plasmids using Lipofectamine. Enzyme linked immunosorbent assay (ELISA) was confirm expression cells. The fibrosarcoma established by subcutaneous injection Balb/C mice. Mice sacrificed tumors extracted. Tumor sizes measured caliper. IFN-γ studied real-time PCR western blotting. Ki-67(a proliferation marker) immunohistochemistry staining. Results discussion group treated showed significant decrease volume (P: 0.000). results blotting that increased (relative IL-12: 1.9 relative IFN-γ: 1.766). Immunohistochemistry staining Ki-67 reduced IL-12. Conclusion successfully led regress model. This may serve candidate approach